Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Centers for Disease Control and Prevention (CDC)
---Centers for Medicare and Medicaid Services (CMS)
---Food & Drug Administration (FDA)
---Health Resources and Services Administration (HRSA)
---National Institutes of Health (NIH)

FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---CMMI Models: GLOBE and GUARD
---Funding for Section 317
---Funding for Strategic National Stockpile
---Pandemic Preparedness
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Vaccine Access & Compensation

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Antitrust Legislation
---Oversight Pharmacy Benefit Managers

Artificial Intelligence (AI)
---Patentability of AI Assisted Inventions

Bayh-Dole Act/Tech Transfer
---Bayh-Dole Act

Compulsory Licensing
---28 U.S.C. 1498 - Patent and copyright cases

Data Privacy
---H.R.8413: SECURE Data Act
---Implementation of BIOSECURE Act

Drug Patenting
---H.R.3160/S.1553: PREVAIL Act
---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act
---H.R.9142: Prohibiting Adversarial Patents Act of 2026
---S.43/H.R.6485: Skinny Labels, Big Savings Act
---S.527: Prescription Pricing for the People Act
---S.1041: Affordable Prescriptions for Patients Act
---S.1095: Stop STALLING Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1097: Interagency Patent Coordination and Improvement Act
---S.1546/H.R.3152: Patent Eligibility Restoration Act (PERA)
---S.2658: Medication Affordability and Patient Integrity Act
---S.3014: Ensuring Timely Access to Generics Act
---Department of Commerce Patent Valuation Fee Proposal
---PTAB Reform
---PTO Proposed Rules on Terminal Disclaimer Practice
---Restrictions on Intellectual Property Rights
---Section 101 Modernization

Foreign Drug Data Protection Law
---Implementation of BIOSECURE Act

Intellectual Property Enforcement
---China

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), Commerce - Dept of (DOC), Natl Institutes of Health (NIH)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Administration for Strategic Preparedness and Response (ASPR)
---Centers for Disease Control and Prevention (CDC)
---Centers for Medicare and Medicaid (CMS)
---Food & Drug Administration (FDA)
---Health Resources and Services Administration (HRSA)
---National Institutes of Health (NIH)

FY 2026 Appropriations for Specific Issues
---Alternative Funding Programs
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---CICP
---CMMI: GLOBE and GUARD Models
---Drug Pricing
---Funding for Strategic National Stockpile
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Influenza Planning & Response
---MCM PRV Reauthorization
---Pandemic Preparedness -R&D Funding for Medical Countermeasures
---Pediatric Priority Review Voucher
---Prescription Drug User Fee Act (PDUFA) VIII Implementation
---Project Bioshield
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Section 317 Immunization Program
---Vaccines and Infectious Diseases
---Vaccine Injury Compensation Program

340B Drug Discount Program
---H.R.5256: 340B ACCESS Act
---H.R.9504: Tax Exempt Hospital Transparency Act
---H.R.9599: SECURE 340B Act
---S.5244: SUSTAIN 340B Act
---Program Implementation & Oversight
---Rebate Models

Accelerated Approval

Artificial Intelligence (AI)

Alternative Funding Programs

Biodefense Research, Development and Procurement Issues (Non-Funding)
---Gain of function (Viral Gain of Function Research Moratorium Act, SAFE Risky Research Act)
---Implementation of BIOSECURE Act
---MCM PRV Program Reauthorization
---National Defense Authorization Act 2027
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Risky Research Review Act
---VICP Loopholes

Biosimilars
---H.R.10628/S.5571: Biosimilars Access and Affordability Act
---S.1414: Expedited Access to Biosimilars Act
---S.1954: Biosimilar Red Tape Elimination Act
---Biosimilars Competition (General)
---Interchangeability and Pharmacy Substitution

Cell & Gene Therapy
---H.R.1672: Maintaining Investments in New Innovation (MINI) Act

Clinical Trial Data in China
---Next-Generation U.S. Clinical Development to Accelerate Cures - Legislative Discussion Draft

Data Privacy
---H.R.8413: SECURE Data Act
---Clinical Trial Data in China
---Implementation of BIOSECURE Act

Diagnostics and Personalized Medicine Regulation and Oversight

Diversity & Inclusion
---H.R.3521: Clinical Trial Modernization Act
---Decentralized Clinical Trials

Drug Evaluation and Review
---S.43/H.R.6485: Skinny Labels, Big Savings Act
---FDA Hiring Flexibility

Drug Importation

Drug Manufacturing, Quality & Distribution
---S.3788: CLEAR Labels Act
---Advanced Manufacturing
---Compounding Pharmacies
---Drug Shortages
---Supply Chain Integrity and Traceability

Drug Patenting
---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act
---S.43/H.R.6485: Skinny Labels, Big Savings Act
---S.527: Prescription Pricing for the People Act
---S.1041: Affordable Prescriptions for Patients Act
---S.1095: Stop STALLING Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1097: Interagency Patent Coordination and Improvement Act
---S.2658: Medication Affordability and Patient Integrity Act

Drug Pricing
---H.R.1492/S.832: Ensuring Pathways to Innovative Cures (EPIC) Act
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act
---H.R.5391/S.2764 Protecting Patient Access to Cancer and Complex Therapies Act
---H.R.9418: Access to Innovative Treatments Act of 2026
---S.526: Pharmacy Benefit Manager Transparency Act
---S.1097: Interagency Patent Coordination and Improvement Act
---S.1954: Biosimilar Red Tape Elimination Act
---S.3014: Ensuring Timely Access to Generics
---CMMI Authority
---Ensuring Access to Generic Medications Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Implementation of ORPHAN Cures Act
---International Pricing Policies
---Tariffs

Efforts to Expand the Bioeconomy & Biomanufacturing
---H.R.8930: Federal Biotechnology Workforce Assessment Act
---H.R.8938: Biotechnology Workforce Alignment Act of 2026

Foreign Drug Data Protection Law
---Implementation of BIOSECURE Act

Generic Drug Entry
---S.43/H.R.6485: Skinny Labels, Big Savings Act
---S.1095: Stop STALLING Act
---Generic Drug Application Review Reforms
---Incentives for Generic Entry

Issues Relating to Medical Research and Animal Testing
---FDA Modernization Act 3.0

Medicaid
---S.526: Pharmacy Benefit Manager Transparency Act
---Alternative Payment Arrangements for Gene Therapies
---Drug Benefit Design
---Most Favored Nation Drug Pricing Proposals
---Pricing and Rebates

National Defense
---Medical Countermeasure Priority Review Voucher Reauthorization
---H.R.8800: National Defense Authorization Act for Fiscal Year 2027

National Security
---H.R.10568: Protecting Biological Data as Critical Infrastructure Act
---H.R.10569: Protecting Biotechnology and Biomanufacturing as Critical Infrastructure Act
---S.3741: Biosecurity Modernization and Innovation Act of 2026
---Clinical Trial Data in China
---CMMI: GLOBE and GUARD Models
---Implementation of BIOSECURE Act
---International Pricing Policies
---Medical Countermeasure Priority Review Voucher Reauthorization
---NSC/OSTP priorities
---Nucleic acid synthesis security and biotechnology governance

Opioid Crisis
---Non-Opioid Analgesics

Orphan Drug Issues
---H.R.1414: Cameron's Law
---Implementation of ORPHAN Cures Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Orphan Drug Tax Credit

Pandemic Preparedness
---Drug Supply Chain Management
---R&D Funding for Medical Countermeasures
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Supply Chain Issues

Precision Medicine Initiative

Rare Pediatric Disease Priority Review
---H.R.10359: Priority for Pediatric Cures Act
---S.822: Scientific EXPERT Act
---Rare Disease Pilot Program

Reimbursement and Coverage of Innovative Products
---H.R.5509/S.2903:SAFE STEP Act
---S.864/H.R.6423: HELP Copays Act
---Access to Innovative Treatments
---CMMI Authority
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Medicare Part B Physician-Administered Products
---National Coverage Determination
---Patient Cost-Sharing and Smoothing
---Prior Authorization Reform
---Protected Classes
---Step Therapy
---Support of Patient Premiums and Cost-Sharing Obligations
---Value-Based Contracting and Communications
---Value-Based Purchasing (VBP) Rule

Vaccines and Infectious Diseases
---H.R.5509/S.2903: SAFE STEP Act
---H.R.7352/S.4875: PASTEUR Act of 2026
---H.R.9418: Access to Innovative Treatments Act of 2026
---H.R.9672: Vaccine Injury Compensation Modernization Act of 2026
---Adult Immunization
---Maternal Immunization
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---Monoclonal Antibody Coverage and Utilization
---Senate Discussion Draft - Vaccine Injury Protection Act
---Vaccine and Antimicrobial Resistance Product Development and Incentives
---Vaccine Injury Compensation Program
---Vaccine Safety
---Vaccine Safety Net and Vaccine Infrastructure
---Value of Vaccines and Vaccine Confidence

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Natl Security Council (NSC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Centers for Disease Control and Prevention Vaccine Programs
---Health Resources and Services Administration (HRSA)

FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Funding for Strategic National Stockpile
---Pandemic Preparedness - R&D Funding for Medical Countermeasures
---Prescription Drug User Fee Act (PDUFA) VIII Implementation
---VICP/CICP

Biodefense Research, Development and Procurement Issues
---H.R.1980: State Strategic Stockpile Act
---H.R.8800: National Defense Authorization Act for Fiscal Year 2027
---Ebola BDBV Outbreak
---Hanta Virus
---Medical Countermeasure Priority Review Voucher Reauthorization
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)

National Security
---H.R.10568: Protecting Biological Data as Critical Infrastructure Act
---H.R.10569: Protecting Biotechnology and Biomanufacturing as Critical Infrastructure Act
---S.3741: Biosecurity Modernization and Innovation Act of 2026

Pandemic Preparedness
---Drug Supply Chain Management
---Medical Countermeasure Priority Review Voucher Reauthorization
---Supply Chain Issues

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Administration for Strategic Preparedness and Response (ASPR)
---Biomedical Advanced Research and Development Authority (BARDA)
---Centers for Disease Control and Prevention (CDC)
---Food & Drug Administration (FDA)
---Health Resources and Services Administration (HRSA)
---National Institutes of Health (NIH)

FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Funding for Medical Countermeasures
---Funding for Section 317
---Funding for Strategic National Stockpile
---Pandemic Preparedness - R&D Funding for Medical Countermeasures
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---VICP/CICP

Antimicrobial Resistance
---H.R.7352/S.4875: PASTEUR Act of 2026

Biodefense Research, Development and Procurement Issues
---Medical Countermeasure Priority Review Voucher Reauthorization

CDC Reform

Pandemic Preparedness
---Medical Countermeasure Priority Review Voucher Reauthorization
---R&D Funding for Medical Countermeasures

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Alternative Funding Programs
---Antimicrobial Resistance (General)
---CMMI: GLOBE and GUARD Models
---Drug Pricing
---Pandemic Preparedness - R&D Funding for Medical Countermeasures
---Vaccines and Infectious Diseases

340B Drug Discount Program
---H.R.5256: 340B ACCESS Act
---H.R.9504: Tax Exempt Hospital Transparency Act
---H.R.9599: SECURE 340B Act
---S.5244: SUSTAIN 340B Act
---Program Implementation & Oversight
---Rebate Models

Accelerated Approval

Artificial Intelligence (AI)

Alternative Funding Programs

Biosimilars
---H.R.10628/S.5571: Biosimilars Access and Affordability Act
---S.1954: Biosimilars Red Tape Elimination Act
---Interchangeability and Pharmacy Substitution

Cell & Gene Therapy
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act
---H.R.7871/S.1637: MVP Act

Clinical Trial Data in China

Data Privacy
---H.R.8413: SECURE Data Act

Diversity & Inclusion
---Decentralized Clinical Trials

Drug Evaluation and Review
---FDA Hiring Flexibility

Drug Importation

Drug Manufacturing, Quality & Distribution
---Advanced Manufacturing
---Compounded Medicines
---Drug Shortages
---Supply Chain Integrity and Traceability

Drug Patenting
---S.43/H.R.6485: Skinny Labels, Big Savings Act
---S.527: Prescription Pricing for the People Act
---S.1095: Stop STALLING Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1097: Interagency Patent Coordination and Improvement Act
---Patent Thickets
---Restrictions on Intellectual Property Rights

Drug Pricing
---H.R.946: ORPHAN Cures Act
---H.R.1492/S.832: Ensuring Pathways to Innovative Cures (EPIC) Act
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act
---H.R.6166: Lowering Drug Costs for American Families Act
---S.526: Pharmacy Benefit Manager Transparency Act
---S.527: Prescription Pricing for the People Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---CMMI Authority
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Most Favored Nation Drug Pricing Proposals
---Patient Cost-Sharing and Implementation
---PBM Reform

Foreign Drug Data Protection Laws
---Regulatory Harmonization

Medicaid
---S.526: Pharmacy Benefit Manager Transparency Act
---Alternative Payment Arrangements for Gene Therapies
---CMMI (GENEROUS Model)
---Drug Benefit Design
---Medicaid Drug Rebate Program
---Most Favored Nation in Medicaid
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule

Opioid Crisis
---Coverage and Reimbursement

Orphan Drug Issues
---H.R.1414: Cameron's Law
---H.R.6166: Lowering Drug Costs for American Families Act
---H.R.10359: Priority for Pediatric Cures Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Orphan Drug Tax Credit

Pandemic Preparedness
---Drug Supply Chain Management
---Medical Countermeasure Priority Review Voucher Reauthorization
---Monoclonal Antibody Coverage and Utilization
---R&D Funding for Medical Countermeasures
---WHO Pandemic Preparedness Accord

Reimbursement and Coverage of Innovative Products
---H.R.6166: Lowering Drug Costs for American Families Act
---S.864/H.R.6423: HELP Copays Act
---CMMI Authority
---Medicare Part B Physician-Administered Products
---National Coverage Determination
---Patient Cost-Sharing and Smoothing
---Protected Classes
---Support of Patient Premiums and Cost-Sharing Obligations

Vaccines and Infectious Diseases
---Adult Immunization
---Countermeasures Injury Compensation Program
---Maternal Immunization
---MCM Manufacturing & Capacity
---Medical Countermeasure Priority Review Voucher Reauthorization
---Vaccine Injury Compensation Program
---Vaccine Safety and Quality
---Vaccine Safety Net and Vaccine Infrastructure
---Value of Vaccines and Vaccine Confidence

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Banking Policy Impacting Emerging Companies
---Regulatory Burden

Capital Formation Incentives
---H.R.3323: Helping Startups Continue To Grow Act
---H.R.3339: Equal Opportunity for All Investors Act of 2025
---H.R.3348: Accredited Investor Definition Review Act
---H.R.3382/S.2924: Small Entity Update Act
---H.R.3394: Fair Investment Opportunities for Professional Experts Act
---H.R.4430: Expanding WKSI Eligibility Act

Capital Market Enhancements
---Accredited Investor Definition
---Market Liquidity Proposals
---Public Float Threshold Update

Small Business Innovation Research (SBIR) Program
---H.R.3169/S.1573: SBIR/STTR Reauthorization Act of 2025
---H.R.4777: INNOVATE Act
---H.R.5100: To extend the SBIR and STTR programs, and for other purposes.
---Implementation of SBIR/STTR reauthorization

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Vaccines and Infectious Diseases
---VICP/CICP

Capital Formation Incentives
---Net Operating Loss Advance Refunds

Orphan Drug Issues
---H.R.1414: Cameron's Law
---H.R.10359: Priority for Pediatric Cures Act

Pandemic Preparedness

Research & Development Tax Credit Reforms
---H.R.1: One Big Beautiful Bill Act
---H.R.1414: Cameron's Law
---Expensing of R&D Expenditures

Vaccines and Infectious Disease
---H.R.9672: Vaccine Injury Compensation Modernization Act of 2026
---Senate Discussion Draft - Vaccine Injury Protection Act
---VICP

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

CFIUS and Foreign Investment
---H.R.9102: BINSA Act
---Outbound Investment Security Program

Drug Importation

Drug Pricing
---CMMI: GLOBE and GUARD Models
---International Pricing Policies
---Most Favored Nation Drug Pricing Proposals
---Reference Pricing in Drug Reimbursement
---Tariffs

Foreign Drug Data Protection Laws
---Implementation of BIOSECURE Act
---Implementation of COINS

Global Supply Chain Resiliency

Incentives for Domestic Manufacturing

Intellectual Property International Enforcement

Synthetic Biotech

Tariffs
---General
---Section 232 Tariffs on Pharmaceuticals and Pharmaceutical Ingredients

US-China Trade Relations
---H.R.9102: BINSA Act
---Implementation of COINS

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), Natl Security Council (NSC), Treasury - Dept of, State - Dept of (DOS), U.S. Trade Representative (USTR), Executive Office of the President (EOP)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes